BRPI0918653A2 - combinação de inibidor de ns3 protese de hcv com interferon e ribavirina. - Google Patents

combinação de inibidor de ns3 protese de hcv com interferon e ribavirina.

Info

Publication number: BRPI0918653A2
Authority: BR; Brazil
Prior art keywords: ribavirin; hcv; prosthesis; interferon; inhibitor combination
Prior art date: 2008-09-17

Application number

BRPI0918653A

Other languages

English (en)

Inventor

David Huang

Gerhard Gustav Steinmann

Jerry O Stern

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-09-17

Filing date

2009-09-14

Publication date

2015-12-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41571875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0918653(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-09-14 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2015-12-01 Publication of BRPI0918653A2 publication Critical patent/BRPI0918653A2/pt

Links

102000014150 Interferons Human genes 0.000 title 1
108010050904 Interferons Proteins 0.000 title 1
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
229940079322 interferon Drugs 0.000 title 1
229960000329 ribavirin Drugs 0.000 title 1
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BRPI0918653A 2008-09-17 2009-09-14 combinação de inibidor de ns3 protese de hcv com interferon e ribavirina. BRPI0918653A2 (pt)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US9775308P	2008-09-17	2008-09-17
US10903308P	2008-10-28	2008-10-28
US17193509P	2009-04-23	2009-04-23
PCT/US2009/056771 WO2010033443A1 (en)	2008-09-17	2009-09-14	Combination of hcv ns3 protease inhibitor with interferon and ribavirin

Publications (1)

Publication Number	Publication Date
BRPI0918653A2 true BRPI0918653A2 (pt)	2015-12-01

Family

ID=41571875

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0918653A BRPI0918653A2 (pt)	2008-09-17	2009-09-14	combinação de inibidor de ns3 protese de hcv com interferon e ribavirina.

Country Status (24)

Country	Link
US (1)	US8399484B2 (pt)
EP (1)	EP2337583A1 (pt)
JP (1)	JP5539363B2 (pt)
KR (1)	KR20110054003A (pt)
CN (1)	CN102159245B (pt)
AR (1)	AR073516A1 (pt)
AU (1)	AU2009293493B2 (pt)
BR (1)	BRPI0918653A2 (pt)
CA (1)	CA2737376A1 (pt)
CL (1)	CL2011000571A1 (pt)
CO (1)	CO6351753A2 (pt)
EA (1)	EA019965B1 (pt)
EC (1)	ECSP11010877A (pt)
IL (1)	IL210152A0 (pt)
MA (1)	MA32634B1 (pt)
MX (1)	MX2011002602A (pt)
MY (1)	MY152824A (pt)
NZ (1)	NZ591030A (pt)
PE (1)	PE20110343A1 (pt)
TW (1)	TWI454263B (pt)
UA (1)	UA103496C2 (pt)
UY (1)	UY32124A (pt)
WO (1)	WO2010033443A1 (pt)
ZA (1)	ZA201009151B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UY32099A (es)	2008-09-11	2010-04-30	Enanta Pharm Inc	Inhibidores macrocíclicos de serina proteasas de hepatitis c
AU2009293493B2 (en)	2008-09-17	2014-09-18	Boehringer Ingelheim International Gmbh	Combination of HCV NS3 protease inhibitor with interferon and ribavirin
AR075584A1 (es) *	2009-02-27	2011-04-20	Intermune Inc	COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
CN105001302A (zh) *	2009-09-28	2015-10-28	英特穆恩公司	C型肝炎病毒复制的环肽抑制剂
KR20120106942A (ko) *	2009-10-30	2012-09-27	베링거 인겔하임 인터내셔날 게엠베하	Ｂｉ２０１３３５, 인터페론 알파 및 리바비린을 포함하는 ｈｃｖ 병용 치료요법을 위한 투여 용법
WO2012041771A1 (en) *	2010-09-30	2012-04-05	Boehringer Ingelheim International Gmbh	Combination therapy for treating hcv infection
KR20140003521A (ko)	2010-12-30	2014-01-09	이난타 파마슈티칼스, 인코포레이티드	페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제
CN103534256B (zh)	2010-12-30	2016-08-10	益安药业	大环丙型肝炎丝氨酸蛋白酶抑制剂
SG191923A1 (en) *	2011-01-10	2013-08-30	Proteus Digital Health Inc	System, method, and article to prompt behavior change
US10201584B1 (en)	2011-05-17	2019-02-12	Abbvie Inc.	Compositions and methods for treating HCV
US8492386B2 (en)	2011-10-21	2013-07-23	Abbvie Inc.	Methods for treating HCV
CN104023726A (zh)	2011-10-21	2014-09-03	艾伯维公司	用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
US8466159B2 (en)	2011-10-21	2013-06-18	Abbvie Inc.	Methods for treating HCV
DE112012003510T5 (de)	2011-10-21	2015-03-19	Abbvie Inc.	Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
JP2015509980A (ja) *	2012-03-14	2015-04-02	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｈｃｖ−ｈｉｖ同時感染患者集団のｈｃｖ感染症を治療するための併用療法
US20140242029A1 (en) *	2013-02-27	2014-08-28	Boehringer Ingelheim International Gmbh	Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
WO2013147749A1 (en)	2012-03-27	2013-10-03	Boehringer Ingelheim International Gmbh	Oral combination therapy for treating hcv infection in specific patient subgenotype populations
WO2013147750A1 (en)	2012-03-27	2013-10-03	Boehringer Ingelheim International Gmbh	Oral combination therapy for treating hcv infection in specific patient sub-population
WO2013143581A1 (en)	2012-03-28	2013-10-03	Boehringer Ingelheim International Gmbh	Combination therapy for treating hcv infection in specific patient subgenotype sub-population
WO2014138374A1 (en)	2013-03-08	2014-09-12	Boehringer Ingelheim International Gmbh	Oral combination therapy for treating hcv infection in specific patient sub-population
WO2015103490A1 (en)	2014-01-03	2015-07-09	Abbvie, Inc.	Solid antiviral dosage forms
JP7129703B2 (ja)	2016-04-28	2022-09-02	エモリーユニバーシティー	アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4247479A (en)	1976-12-03	1981-01-27	Hoechst Aktiengesellschaft	Process for the manufacture of aromatic amines from α, β-unsaturated cycloaliphatic ketoximes
US6387365B1 (en)	1995-05-19	2002-05-14	Schering Corporation	Combination therapy for chronic hepatitis C infection
US5908621A (en)	1995-11-02	1999-06-01	Schering Corporation	Polyethylene glycol modified interferon therapy
ES2214551T3 (es)	1995-11-02	2004-09-16	Schering Corporation	Terapia de infusion continua de citocinas a baja dosis.
US6172046B1 (en)	1997-09-21	2001-01-09	Schering Corporation	Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6472373B1 (en)	1997-09-21	2002-10-29	Schering Corporation	Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
JP3839667B2 (ja)	1998-06-08	2006-11-01	エフ．ホフマン−ラロシュアーゲー	慢性Ｃ型肝炎の処置のためのＰｅｇ−ＩＮＦ−アルファ及びリバビリンの使用
US6323180B1 (en)	1998-08-10	2001-11-27	Boehringer Ingelheim (Canada) Ltd	Hepatitis C inhibitor tri-peptides
US6824768B2 (en)	1998-12-18	2004-11-30	Schering Corporation	Ribavirin-pegylated interferon alfa induction HCV combination therapy
US6608027B1 (en)	1999-04-06	2003-08-19	Boehringer Ingelheim (Canada) Ltd	Macrocyclic peptides active against the hepatitis C virus
US6849254B1 (en)	1999-04-19	2005-02-01	Schering Corporation	HCV combination therapy
JP3930428B2 (ja)	2000-08-09	2007-06-13	エフ．ホフマン−ラロシュアーゲー	抗炎症剤としてのキノリン誘導体
EP2335700A1 (en)	2001-07-25	2011-06-22	Boehringer Ingelheim (Canada) Ltd.	Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US6867185B2 (en)	2001-12-20	2005-03-15	Bristol-Myers Squibb Company	Inhibitors of hepatitis C virus
US7119072B2 (en)	2002-01-30	2006-10-10	Boehringer Ingelheim (Canada) Ltd.	Macrocyclic peptides active against the hepatitis C virus
US20050075279A1 (en)	2002-10-25	2005-04-07	Boehringer Ingelheim International Gmbh	Macrocyclic peptides active against the hepatitis C virus
US7601709B2 (en)	2003-02-07	2009-10-13	Enanta Pharmaceuticals, Inc.	Macrocyclic hepatitis C serine protease inhibitors
EP1615947A2 (en)	2003-04-10	2006-01-18	Boehringer Ingelheim International GmbH	Process for preparing macrocyclic compounds
KR20060008877A (ko)	2003-04-10	2006-01-27	베링거 인겔하임 인터내셔날 게엠베하	루테늄 착물 촉매 존재하의 복분해 반응에 의한거대사이클릭 화합물의 제조방법
ATE422895T1 (de)	2003-04-16	2009-03-15	Bristol Myers Squibb Co	Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
CL2004001161A1 (es) *	2003-05-21	2005-04-08	Boehringer Ingelheim Int	Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
CN1835765A (zh)	2003-08-13	2006-09-20	霍华德·J·史密斯及同仁控股有限公司	治疗病毒感染的方法
EP1673385B1 (en)	2003-09-22	2011-03-02	Boehringer Ingelheim International GmbH	Macrocyclic peptides active against the hepatitis c virus
AR045870A1 (es)	2003-10-11	2005-11-16	Vertex Pharma	Terapia de combinacion para la infeccion de virus de hepatitis c
US7491794B2 (en)	2003-10-14	2009-02-17	Intermune, Inc.	Macrocyclic compounds as inhibitors of viral replication
US7410979B2 (en)	2003-11-19	2008-08-12	Rigel Pharmaceuticals, Inc.	Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections
CN1922174A (zh)	2004-02-20	2007-02-28	贝林格尔·英格海姆国际有限公司	病毒聚合酶抑制剂
ES2338666T3 (es)	2004-03-15	2010-05-11	Boehringer Ingelheim International Gmbh	Procedimiento para la preparacion de dipeptidos macrociclicos adecuados para el tratamiento de infecciones viricas de la hepatitis c.
EP1749007A2 (en)	2004-03-30	2007-02-07	Intermune, Inc.	Macrocyclic compounds as inhibitors of viral replication
EP1753775B1 (en)	2004-05-25	2012-12-26	Boehringer Ingelheim International GmbH	Process for preparing acyclic hcv protease inhibitors
DE102004033312A1 (de)	2004-07-08	2006-01-26	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Kontinuierliches Metatheseverfahren mit Ruthenium-Katalysatoren
BRPI0513370A (pt)	2004-07-14	2008-05-06	Novartis Ag	uso de uma combinação de ciclosporina e interferonas peguilados para tratamento de hepatite c (hcv)
US7375218B2 (en)	2004-09-17	2008-05-20	Boehringer Ingelheim International Gmbh	Process for preparing macrocyclic HCV protease inhibitors
US7189844B2 (en)	2004-09-17	2007-03-13	Boehringer Ingelheim International Gmbh	Ring-closing metathesis process in supercritical fluid
PE20070211A1 (es)	2005-07-29	2007-05-12	Medivir Ab	Compuestos macrociclicos como inhibidores del virus de hepatitis c
MX2008010355A (es)	2006-02-09	2008-10-31	Schering Corp	Combinaciones que comprenden inhibidores de proteasa del virus de la hepatitis c e inhibidores de polimerasa del virus de la hepatitis c, y metodos de tratamiento relacionados con los mismos.
WO2008070358A2 (en) *	2006-11-16	2008-06-12	Phenomix Corporation	N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain
NZ582096A (en)	2007-06-29	2012-05-25	Gilead Sciences Inc	Antiviral compounds that inhibit hepatitis c virus (hcv)
AR068794A1 (es)	2007-06-29	2009-12-09	Gilead Sciences Inc	Compuestos antivirales
WO2009014730A1 (en)	2007-07-26	2009-01-29	Idenix Pharmaceuticals, Inc.	Macrocyclic serine protease inhibitors
WO2009021121A2 (en)	2007-08-08	2009-02-12	Wyeth	Identification and characterization of hcv replicon variants with reduced susceptibility to a combination of polymerase and protease inhibitors, and methods related thereto
RU2490272C2 (ru)	2008-02-04	2013-08-20	Айденикс Фармасьютикалз, Инк.	Макроциклические ингибиторы серинпротеазы
AU2009293494B2 (en)	2008-09-16	2014-04-24	Boehringer Ingelheim International Gmbh	Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent HCV inhibitor
AU2009293493B2 (en)	2008-09-17	2014-09-18	Boehringer Ingelheim International Gmbh	Combination of HCV NS3 protease inhibitor with interferon and ribavirin
TW201023858A (en)	2008-09-18	2010-07-01	Ortho Mcneil Janssen Pharm	Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside
PE20120322A1 (es)	2009-07-07	2012-04-14	Boehringer Ingelheim Int	Composicion farmaceutica que comprende faldaprevir o una sal del mismo en un vehiculo auto-emulsionante
KR20120106942A (ko)	2009-10-30	2012-09-27	베링거 인겔하임 인터내셔날 게엠베하	Ｂｉ２０１３３５, 인터페론 알파 및 리바비린을 포함하는 ｈｃｖ 병용 치료요법을 위한 투여 용법
US8530497B2 (en)	2010-03-11	2013-09-10	Boehringer Ingelheim International Gmbh	Crystalline salts of a potent HCV inhibitor
WO2012041771A1 (en)	2010-09-30	2012-04-05	Boehringer Ingelheim International Gmbh	Combination therapy for treating hcv infection

2009
- 2009-09-14 AU AU2009293493A patent/AU2009293493B2/en not_active Ceased
- 2009-09-14 BR BRPI0918653A patent/BRPI0918653A2/pt not_active IP Right Cessation
- 2009-09-14 PE PE2011000635A patent/PE20110343A1/es not_active Application Discontinuation
- 2009-09-14 EP EP09792492A patent/EP2337583A1/en not_active Withdrawn
- 2009-09-14 NZ NZ591030A patent/NZ591030A/xx not_active IP Right Cessation
- 2009-09-14 CA CA2737376A patent/CA2737376A1/en not_active Abandoned
- 2009-09-14 MX MX2011002602A patent/MX2011002602A/es active IP Right Grant
- 2009-09-14 WO PCT/US2009/056771 patent/WO2010033443A1/en not_active Ceased
- 2009-09-14 KR KR1020117005679A patent/KR20110054003A/ko not_active Ceased
- 2009-09-14 UA UAA201104531A patent/UA103496C2/uk unknown
- 2009-09-14 MY MYPI20111139 patent/MY152824A/en unknown
- 2009-09-14 CN CN2009801362929A patent/CN102159245B/zh not_active Expired - Fee Related
- 2009-09-14 EA EA201100506A patent/EA019965B1/ru not_active IP Right Cessation
- 2009-09-14 JP JP2011527889A patent/JP5539363B2/ja not_active Expired - Fee Related
- 2009-09-16 TW TW098131293A patent/TWI454263B/zh not_active IP Right Cessation
- 2009-09-16 UY UY0001032124A patent/UY32124A/es not_active Application Discontinuation
- 2009-09-16 AR ARP090103556A patent/AR073516A1/es unknown
- 2009-09-16 US US12/560,752 patent/US8399484B2/en active Active
2010
- 2010-12-20 ZA ZA2010/09151A patent/ZA201009151B/en unknown
- 2010-12-21 IL IL210152A patent/IL210152A0/en unknown
2011
- 2011-03-09 EC EC2011010877A patent/ECSP11010877A/es unknown
- 2011-03-14 MA MA33700A patent/MA32634B1/fr unknown
- 2011-03-16 CO CO11032826A patent/CO6351753A2/es not_active Application Discontinuation
- 2011-03-17 CL CL2011000571A patent/CL2011000571A1/es unknown

Also Published As

Publication number	Publication date
CN102159245B (zh)	2013-07-24
TWI454263B (zh)	2014-10-01
CA2737376A1 (en)	2010-03-25
ZA201009151B (en)	2011-09-28
TW201016218A (en)	2010-05-01
EA019965B1 (ru)	2014-07-30
US20100068182A1 (en)	2010-03-18
MX2011002602A (es)	2011-04-07
NZ591030A (en)	2012-10-26
JP5539363B2 (ja)	2014-07-02
CL2011000571A1 (es)	2011-07-29
MY152824A (en)	2014-11-28
PE20110343A1 (es)	2011-06-25
WO2010033443A1 (en)	2010-03-25
MA32634B1 (fr)	2011-09-01
AU2009293493B2 (en)	2014-09-18
IL210152A0 (en)	2011-03-31
CN102159245A (zh)	2011-08-17
CO6351753A2 (es)	2011-12-20
JP2012502999A (ja)	2012-02-02
AR073516A1 (es)	2010-11-10
EP2337583A1 (en)	2011-06-29
ECSP11010877A (es)	2011-04-29
US8399484B2 (en)	2013-03-19
UY32124A (es)	2010-04-30
EA201100506A1 (ru)	2011-10-31
UA103496C2 (uk)	2013-10-25
KR20110054003A (ko)	2011-05-24
HK1156865A1 (en)	2012-06-22
AU2009293493A1 (en)	2010-03-25

Legal Events

Date	Code	Title	Description
2016-09-20	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 7A ANUIDADE.
2017-01-17	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
ZA201009151B (en)	2011-09-28	Combination of hcv ns3 protease inhibitor with interferon and ribavirin
ATE501156T1 (de)	2011-03-15	Cyclopropyl-annelierte indolobenzazepine als hcv- ns5b-inhibitoren
EP2076278A4 (en)	2012-12-26	HCV NS3 proteinase inhibitor
EP2271345A4 (en)	2011-08-31	HCV NS3 proteinase inhibitor
DK2084175T3 (da)	2011-04-18	HCV nucleosidinhibitor
DK2373172T3 (da)	2013-10-21	Hcv-ns5a-hæmmere
ECSP088157A (es)	2008-02-20	Inhibidores de proteasa ns3 del vhc
EP2079480A4 (en)	2011-06-15	HCV NS3 proteinase inhibitor
BRPI0923184A2 (pt)	2019-09-24	inibidores de hcv ns3 protease
EP2125870A4 (en)	2011-04-06	INHIBITORS OF HEPATITIS C NS3 PROTEASE
EP2083844A4 (en)	2010-12-01	INHIBITORS OF HCV NS3 PROTEASE
IL194434A0 (en)	2011-08-01	Hcv/hiv inhibitors and their uses
EP2079479A4 (en)	2010-12-22	Hcv ns3 protease inhibitors
CR8540A (es)	2009-01-16	Inhibidores de serina proteasa ns-3 del vhc
DK1924593T3 (da)	2010-01-25	HCV NS3-proteaseinhibitorer
IL213278A0 (en)	2011-07-31	Inhibitors of hcv ns5a
IL198401A0 (en)	2010-02-17	Hcv ns3 protease inhibitors
CY2015004I1 (el)	2016-08-31	Αναστολεις του ιου της ηπατιτιδας c
ES2355534T8 (es)	2011-05-09	Derivados de isoquinolina e isoquinolinona sustituidos con cicloalquilamina.
IL194777A0 (en)	2011-08-01	Hcv coreceptor and methods of use thereof
EP2237667A4 (en)	2012-05-16	HCV PROTEASE INHIBITORS AND USES THEREOF
BRPI0919404A2 (pt)	2015-12-15	combinações sinergísticas de um inibidor macrocíclico do hcv e de um nucleosídeo
EP1994491A4 (en)	2010-11-17	FLAVIVIRUS INHIBITION WITH SULTAMES AND RELATED COMPOUNDS
BRPI0721216A2 (pt)	2014-12-02	Composições de acetaminofen com efeitos colaterais minimizados e hepatotoxidez reduzida
CR10430A (es)	2009-01-15	Aminothiazoles and their uses